CLARENCE, N.Y.--(BUSINESS WIRE)--
22nd Century Group, Inc. (NYSE MKT:XXII) today announced that Henry Sicignano III, President, will present at the LD MICRO Invitational Conference at the Luxe Sunset Hotel, Los Angeles, California, on Wednesday, June 4th, 2014 at 9:00am PDT.
22nd Century Group’s presentation at the LD Micro Invitational Conference is part of a one-week non-deal road show. The Company will also be conducting private meetings at the conference over the course of the day.
Starting June 2, 2014, Joseph Pandolfino, CEO, and Henry Sicignano, President, will visit five cities across the United States to introduce 22nd Century Group to institutional investors, retail brokers, and the business press. This initiative represents the Company’s first major effort to specifically target institutional investors since uplisting to the NYSE MKT exchange in March 2014.
Though the Company’s shareholder base has increased from fewer than 100 shareholders in early 2011 to more than 2,000 shareholders today, it is clear that 22nd Century Group remains “well under the radar” of most of Wall Street. It is management’s intention that the Company’s road show increases awareness of 22nd Century Group’s technology and investment potential.
About LD Micro
LD MICRO is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks, as well as comprehensive reports on select companies throughout the year. The firm also hosts the LD MICRO Micro-Cap Growth Conference for investors in December of each year. It is a non-registered investment advisor. For more information, please call 408-457-1042 or visit www.LDmicro.com.
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in the tobacco plant to be decreased or increased through genetic engineering and plant breeding. 22nd Century owns or is the exclusive licensee of 116 issued patents in 78 countries plus an additional 42 pending patent applications. Goodrich Tobacco Company, LLC and Hercules Pharmaceuticals, LLC are wholly-owned subsidiaries of 22nd Century. Goodrich Tobacco is focused on commercial tobacco products and potentially less harmful cigarettes. Hercules Pharmaceuticals is focused on X-22, a prescription smoking cessation aid in development.
For additional information, please visit: www.xxiicentury.com
Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2013, filed on January 30, 2014, including the section entitled “Risk Factors,” and our other reports filed with the U.S. Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.
- Canada International News
- Health Care Industry
- 22nd Century
Tom Redington, 203-222-7399